The nitric oxide-cyclic GMP pathway regulates FoxO and alters dopaminergic neuron survival in drosophila

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Kanao, Tomoko ^a   Sawada, Tomoyo ^b,c   Davies, Shireen Anne ^d   Ichinose, Hiroshi ^e   Hasegawa, Kazuko ^f   Takahashi, Ryosuke ^b,c   Hattori, Nobutaka ^a,c   Imai, Yuzuru ^a  

^a JUNTENDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

^e TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

^f SAGAMIHARA NATIONAL HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; CYCLIC GMP DEPENDENT PROTEIN KINASE II; LEUCINE RICH REPEAT KINASE 2; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR FOXO; UNCLASSIFIED DRUG; CELL RECEPTOR; DROSOPHILA PROTEIN; FORKHEAD TRANSCRIPTION FACTOR; FOXO PROTEIN, DROSOPHILA; GUANYLATE CYCLASE; SOLUBLE GUANYLYL CYCLASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ACTIVATION; CELL SURVIVAL; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DROSOPHILA; EMBRYO; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PARKINSON DISEASE; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; ANIMAL; BIOCHEMISTRY; BIOLOGICAL MODEL; CELL LINE; CELL STRAIN HEK293; CYTOLOGY; DEGENERATIVE DISEASE; METABOLISM; METHODOLOGY; MOUSE; MUTATION; NERVE CELL; PHOSPHORYLATION;

MAMMALIA;

ANIMALS; BIOCHEMISTRY; CELL LINE; CELL SURVIVAL; CYCLIC GMP; DOPAMINERGIC NEURONS; DROSOPHILA; DROSOPHILA PROTEINS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GUANYLATE CYCLASE; HEK293 CELLS; HUMANS; MICE; MODELS, BIOLOGICAL; MODELS, GENETIC; MUTATION; NEURODEGENERATIVE DISEASES; NEURONS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PHOSPHORYLATION; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SIGNAL TRANSDUCTION;

EID: 84857680450     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030958     Document Type: Article

References (62)

1. Steinert JR, Chernova T, Forsythe ID, (2010) Nitric oxide signaling in brain function, dysfunction, and dementia. Neuroscientist 16: 435-452.
2. West AR, Tseng KY, (2011) Nitric Oxide-Soluble Guanylyl Cyclase-Cyclic GMP Signaling in the Striatum: New Targets for the Treatment of Parkinson's Disease? Front Syst Neurosci 5: 55.
3. Hunot S, Boissiere F, Faucheux B, Brugg B, Mouatt-Prigent A, et al. (1996) Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience 72: 355-363.
4. Eve DJ, Nisbet AP, Kingsbury AE, Hewson EL, Daniel SE, et al. (1998) Basal ganglia neuronal nitric oxide synthase mRNA expression in Parkinson's disease. Brain Res Mol Brain Res 63: 62-71.
5. Liberatore GT, Jackson-Lewis V, Vukosavic S, Mandir AS, Vila M, et al. (1999) Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med 5: 1403-1409.
6. Muramatsu Y, Kurosaki R, Watanabe H, Michimata M, Matsubara M, et al. (2003) Cerebral alterations in a MPTP-mouse model of Parkinson's disease-an immunocytochemical study. J Neural Transm 110: 1129-1144.
7. Dreyer J, Schleicher M, Tappe A, Schilling K, Kuner T, et al. (2004) Nitric oxide synthase (NOS)-interacting protein interacts with neuronal NOS and regulates its distribution and activity. J Neurosci 24: 10454-10465.
8. Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, et al. (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44: 595-600.
9. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, et al. (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44: 601-607.
10. Healy DG, Falchi M, O'Sullivan SS, Bonifati V, Durr A, et al. (2008) Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 7: 583-590.
11. Mata IF, Wedemeyer WJ, Farrer MJ, Taylor JP, Gallo KA, (2006) LRRK2 in Parkinson's disease: protein domains and functional insights. Trends Neurosci 29: 286-293.
12. West AB, Moore DJ, Biskup S, Bugayenko A, Smith WW, et al. (2005) Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci U S A 102: 16842-16847.
13. Gloeckner CJ, Kinkl N, Schumacher A, Braun RJ, O'Neill E, et al. (2006) The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum Mol Genet 15: 223-232.
14. Imai Y, Gehrke S, Wang HQ, Takahashi R, Hasegawa K, et al. (2008) Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. Embo J 27: 2432-2443.
15. Lessing D, Bonini NM, (2009) Maintaining the brain: insight into human neurodegeneration from Drosophila melanogaster mutants. Nat Rev Genet 10: 359-370.
16. Kanao T, Venderova K, Park DS, Unterman T, Lu B, et al. (2010) Activation of FoxO by LRRK2 induces expression of proapoptotic proteins and alters survival of postmitotic dopaminergic neuron in Drosophila. Hum Mol Genet 19: 3747-3758.
17. Kalderon D, Rubin GM, (1989) cGMP-dependent protein kinase genes in Drosophila. J Biol Chem 264: 10738-10748.
18. MacPherson MR, Lohmann SM, Davies SA, (2004) Analysis of Drosophila cGMP-dependent protein kinases and assessment of their in vivo roles by targeted expression in a renal transporting epithelium. J Biol Chem 279: 40026-40034.
19. Jarchau T, Hausler C, Markert T, Pohler D, Vanderkerckhove J, et al. (1994) Cloning, expression, and in situ localization of rat intestinal cGMP-dependent protein kinase II. Proc Natl Acad Sci U S A 91: 9426-9430.
20. Kulaksiz H, Rehberg E, Stremmel W, Cetin Y, (2002) Guanylin and functional coupling proteins in the human salivary glands and gland tumors: expression, cellular localization, and target membrane domains. Am J Pathol 161: 655-664.
21. Yuasa K, Yamagami S, Nagahama M, Tsuji A, (2008) Trafficking of cGMP-dependent protein kinase II via interaction with Rab11. Biochem Biophys Res Commun 374: 522-526.
22. Bois PR, Brochard VF, Salin-Cantegrel AV, Cleveland JL, Grosveld GC, (2005) FoxO1a-cyclic GMP-dependent kinase I interactions orchestrate myoblast fusion. Mol Cell Biol 25: 7645-7656.
23. Bicker G, (2007) Pharmacological approaches to nitric oxide signalling during neural development of locusts and other model insects. Arch Insect Biochem Physiol 64: 43-58.
24. Davies S, (2000) Nitric oxide signalling in insects. Insect Biochem Mol Biol 30: 1123-1138.
25. Davies SA, (2006) Signalling via cGMP: lessons from Drosophila. Cell Signal 18: 409-421.
26. Wang X, Robinson PJ, (1997) Cyclic GMP-dependent protein kinase and cellular signaling in the nervous system. J Neurochem 68: 443-456.
27. Hofmann F, Feil R, Kleppisch T, Schlossmann J, (2006) Function of cGMP-dependent protein kinases as revealed by gene deletion. Physiol Rev 86: 1-23.
28. Feil R, Hofmann F, Kleppisch T, (2005) Function of cGMP-dependent protein kinases in the nervous system. Rev Neurosci 16: 23-41.
29. Serulle Y, Zhang S, Ninan I, Puzzo D, McCarthy M, et al. (2007) A GluR1-cGKII interaction regulates AMPA receptor trafficking. Neuron 56: 670-688.
30. de Vente J, Asan E, Gambaryan S, Markerink-van Ittersum M, Axer H, et al. (2001) Localization of cGMP-dependent protein kinase type II in rat brain. Neuroscience 108: 27-49.
31. Feil S, Zimmermann P, Knorn A, Brummer S, Schlossmann J, et al. (2005) Distribution of cGMP-dependent protein kinase type I and its isoforms in the mouse brain and retina. Neuroscience 135: 863-868.
32. Geiselhoringer A, Gaisa M, Hofmann F, Schlossmann J, (2004) Distribution of IRAG and cGKI-isoforms in murine tissues. FEBS Lett 575: 19-22.
33. McGeer PL, Itagaki S, Boyes BE, McGeer EG, (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38: 1285-1291.
34. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH, (2010) Mechanisms underlying inflammation in neurodegeneration. Cell 140: 918-934.
35. Roodveldt C, Christodoulou J, Dobson CM, (2008) Immunological features of alpha-synuclein in Parkinson's disease. J Cell Mol Med 12: 1820-1829.
36. Foley E, O'Farrell PH, (2003) Nitric oxide contributes to induction of innate immune responses to gram-negative bacteria in Drosophila. Genes Dev 17: 115-125.
37. Berger Z, Smith KA, Lavoie MJ, (2010) Membrane localization of LRRK2 is associated with increased formation of the highly active LRRK2 dimer and changes in its phosphorylation. Biochemistry 49: 5511-5523.
38. Greggio E, Zambrano I, Kaganovich A, Beilina A, Taymans JM, et al. (2008) The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation. J Biol Chem 283: 16906-16914.
39. Aquilano K, Baldelli S, Rotilio G, Ciriolo MR, (2008) Role of nitric oxide synthases in Parkinson's disease: a review on the antioxidant and anti-inflammatory activity of polyphenols. Neurochem Res 33: 2416-2426.
40. Tseng KY, Caballero A, Dec A, Cass DK, Simak N, et al. (2011) Inhibition of Striatal Soluble Guanylyl Cyclase-cGMP Signaling Reverses Basal Ganglia Dysfunction and Akinesia in Experimental Parkinsonism. PLoS One 6: e27187.
41. Suzuki N, Motohashi N, Uezumi A, Fukada S, Yoshimura T, et al. (2007) NO production results in suspension-induced muscle atrophy through dislocation of neuronal NOS. J Clin Invest 117: 2468-2476.
42. Soh JW, Kazi JU, Li H, Thompson WJ, Weinstein IB, (2008) Celecoxib-induced growth inhibition in SW480 colon cancer cells is associated with activation of protein kinase G. Mol Carcinog 47: 519-525.
43. Kwon IK, Wang R, Thangaraju M, Shuang H, Liu K, et al. (2010) PKG inhibits TCF signaling in colon cancer cells by blocking beta-catenin expression and activating FOXO4. Oncogene 29: 3423-3434.
44. Lee KS, Iijima-Ando K, Iijima K, Lee WJ, Lee JH, et al. (2009) JNK/FOXO-mediated neuronal expression of fly homologue of peroxiredoxin II reduces oxidative stress and extends life span. J Biol Chem 284: 29454-29461.
45. Hong YK, Lee NG, Lee MJ, Park MS, Choi G, et al. (2009) dXNP/DATRX increases apoptosis via the JNK and dFOXO pathway in Drosophila neurons. Biochem Biophys Res Commun 384: 160-166.
46. Wang MC, Bohmann D, Jasper H, (2005) JNK extends life span and limits growth by antagonizing cellular and organism-wide responses to insulin signaling. Cell 121: 115-125.
47. Puig O, Marr MT, Ruhf ML, Tjian R, (2003) Control of cell number by Drosophila FOXO: downstream and feedback regulation of the insulin receptor pathway. Genes Dev 17: 2006-2020.
48. McGettigan J, McLennan RK, Broderick KE, Kean L, Allan AK, et al. (2005) Insect renal tubules constitute a cell-autonomous immune system that protects the organism against bacterial infection. Insect Biochem Mol Biol 35: 741-754.
49. Venderova K, Kabbach G, Abdel-Messih E, Zhang Y, Parks RJ, et al. (2009) Leucine-Rich Repeat Kinase 2 interacts with Parkin, DJ-1 and PINK-1 in a Drosophila melanogaster model of Parkinson's disease. Hum Mol Genet 18: 4390-4404.
50. Osterwalder T, Yoon KS, White BH, Keshishian H, (2001) A conditional tissue-specific transgene expression system using inducible GAL4. Proc Natl Acad Sci U S A 98: 12596-12601.
51. Udan RS, Kango-Singh M, Nolo R, Tao C, Halder G, (2003) Hippo promotes proliferation arrest and apoptosis in the Salvador/Warts pathway. Nat Cell Biol 5: 914-920.
52. Lu Y, Wu LP, Anderson KV, (2001) The antibacterial arm of the drosophila innate immune response requires an IkappaB kinase. Genes Dev 15: 104-110.
53. Jia J, Tong C, Wang B, Luo L, Jiang J, (2004) Hedgehog signalling activity of Smoothened requires phosphorylation by protein kinase A and casein kinase I. Nature 432: 1045-1050.
54. Junger MA, Rintelen F, Stocker H, Wasserman JD, Vegh M, et al. (2003) The Drosophila forkhead transcription factor FOXO mediates the reduction in cell number associated with reduced insulin signaling. J Biol 2: 20.
55. Yakubovich N, Silva EA, O'Farrell PH, (2010) Nitric oxide synthase is not essential for Drosophila development. Curr Biol 20: R141-142.
56. Muller D, Kugler SJ, Preiss A, Maier D, Nagel AC, (2005) Genetic modifier screens on Hairless gain-of-function phenotypes reveal genes involved in cell differentiation, cell growth and apoptosis in Drosophila melanogaster. Genetics 171: 1137-1152.
57. Yang Y, Gehrke S, Imai Y, Huang Z, Ouyang Y, et al. (2006) Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin. Proc Natl Acad Sci U S A 103: 10793-10798.
58. Zhang X, Gan L, Pan H, Guo S, He X, et al. (2002) Phosphorylation of serine 256 suppresses transactivation by FKHR (FOXO1) by multiple mechanisms. Direct and indirect effects on nuclear/cytoplasmic shuttling and DNA binding. J Biol Chem 277: 45276-45284.
59. Yuasa K, Michibata H, Omori K, Yanaka N, (2000) Identification of a conserved residue responsible for the autoinhibition of cGMP-dependent protein kinase Ialpha and beta. FEBS Lett 466: 175-178.
60. Imai Y, Soda M, Inoue H, Hattori N, Mizuno Y, et al. (2001) An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. Cell 105: 891-902.
61. Imai Y, Soda M, Takahashi R, (2000) Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. J Biol Chem 275: 35661-35664.
62. Kwon Y, Hofmann T, Montell C, (2007) Integration of phosphoinositide- and calmodulin-mediated regulation of TRPC6. Mol Cell 25: 491-503.